Synopsis

Source of validity: Scientific
Rating (out of 5): 2

C-Phycocyanin, a pigment-protein complex derived from Spirulina, has been investigated for its potential hepatoprotective effects, including applications in hepatitis. Scientific evidence for its use primarily comes from preclinical studies (in vitro and animal models), which suggest that C-Phycocyanin possesses antioxidant, anti-inflammatory, and anti-apoptotic properties that may help protect liver cells from damage caused by toxins or viral infections. For instance, several studies in rodents have demonstrated that C-Phycocyanin administration can reduce markers of liver injury (such as ALT and AST), decrease oxidative stress, and inhibit inflammatory cytokine production in models of chemically induced hepatitis. The proposed mechanisms include scavenging reactive oxygen species (ROS), modulating the activity of antioxidant enzymes, and downregulating pro-inflammatory mediators like TNF-α and IL-6. However, there is a lack of robust clinical trials in humans directly evaluating C-Phycocyanin for hepatitis treatment or support. Most human data on Spirulina or its extracts focus on general liver health or non-specific antioxidant effects rather than hepatitis specifically. There is also no established medical guideline endorsing its use for hepatitis. While the preclinical data are promising, the evidence is currently insufficient to firmly recommend C-Phycocyanin as a treatment for hepatitis in humans. Thus, the overall evidence rating is low, reflecting the need for well-designed clinical studies to confirm both efficacy and safety in this context.

More about C-Phycocyanin
More about Hepatitis

Other ingredients used for Hepatitis

Other health conditions supported by C-Phycocyanin

Products containing C-Phycocyanin